Article Link: FDA Approves Gvoke (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia CHICAGO–(BUSINES...
FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)
Article Link: FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD) Se...
FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannula
Article Link: FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannula DUBLIN, Sept. 3, 2019 /PRNewswire/ — Allergan plc ...
FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson’s Disease
Article Link: FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson’s Disease August 27...
FDA Approves Myobloc (rimabotulinumtoxinB) Injection for Chronic Sialorrhea
Article Link: FDA Approves Myobloc (rimabotulinumtoxinB) Injection for Chronic Sialorrhea LOUISVILLE, Ky., Aug. 26, 2019 /PRNewswire/ ...
FDA Approves Taltz (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Article Link: FDA Approves Taltz (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) I...
FDA Approves Xenleta (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
Article Link: FDA Approves Xenleta (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP) DUBLIN, Ireland, Aug. 19, 2019 (GLO...
FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis
Article Link: FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis NORT...
FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis
Article Link: FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis SUMMIT, N.J.–(BUSINESS WIRE)–...
FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
Article Link: FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Na...
